RhoDImmunglobulin

RhoDImmunglobulin, also known as Rh immune globulin or RhoGAM, is a medication used to prevent Rh alloimmunization in Rh-negative individuals. Rh alloimmunization occurs when an Rh-negative person is exposed to Rh-positive blood, typically during pregnancy when an Rh-negative mother carries an Rh-positive fetus. This exposure can trigger the mother's immune system to produce antibodies against the Rh factor. These antibodies can then cross the placenta and attack the red blood cells of future Rh-positive fetuses, leading to a condition called hemolytic disease of the newborn (HDN).

RhoDImmunglobulin works by providing a temporary passive immunity to Rh-positive red blood cells. When administered to an Rh-negative mother, it binds to any fetal Rh-positive red blood cells that may have entered her circulation. This binding prevents the mother's immune system from recognizing these cells as foreign and therefore prevents the production of anti-Rh antibodies.

It is typically administered to Rh-negative pregnant women at around 28 weeks of gestation and again within 72 hours after delivery if the baby is Rh-positive. It is also given after any event that could lead to fetal-maternal hemorrhage, such as amniocentesis, chorionic villus sampling, abdominal trauma, or miscarriage. The prevention of Rh alloimmunization is crucial for ensuring the health of future pregnancies.